Clay B. Siegall

Clay B. Siegall is a declared insider at 5 companies (chief executive); the most frequent names are Seagen Inc., Immunome Inc. and Ultragenyx Pharmaceutical Inc. In total, 401 filings cover trades dated from 6 January 2017 to 23 July 2026.

In open-market terms, that means 9 purchases worth €6.1M on one side and 189 sales worth €104.2M on the other. On balance, insiders were net sellers of €98.1M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 14 share grants and 186 option exercises. Since January 2026: 1 purchase and no sales on the market.

In size, the median ticket on the buying side is €852k. Of 9 purchases, 6 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. For 9 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 44% of cases, with a median move of -2.8%. They describe history only and say nothing certain about the share price ahead.

The newest entry dates from 27 July 2026: a share grant, in Immunome Inc. The last insider purchase was made public on 31 March 2026, 207 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.